Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2022 Financial Results on August 4, 2022
Vir Biotechnology, Inc. (Nasdaq: VIR) announced it will release a corporate update and financial results for Q2 2022 on August 4, 2022, after market close. Investors can access the press release on the company's website. Vir focuses on developing treatments for serious infectious diseases using innovative immunological technologies. Its pipeline includes candidates targeting COVID-19, hepatitis B and D, influenza A, and HIV.
- None.
- None.
SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2022, on Thursday, August 4, 2022.
The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.
About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.
FAQ
What is the date of Vir Biotechnology's Q2 2022 financial results release?
Where can I find the Q2 2022 corporate update from Vir Biotechnology?
What is Vir Biotechnology's focus in drug development?
What diseases is Vir Biotechnology targeting in its pipeline?
